ITC is anticipated to reveal moderate revenue growth, driven by cigarettes and agri businesses, while Sun Pharma is expected to showcase high single-digit bottom-line growth, fueled by strong domestic performance. Revenue growth for Sun Pharma is expected to be 9% year-on-year, while ITC’s revenue is expected to rise 2% year-on-year. Analysts anticipate $500 million in US sales for Sun Pharma.
Highway Infrastructure shares to list today. Here’s what GMP suggests
Highway Infrastructure is set to list on the stock exchanges today. Its IPO saw massive oversubscription across all categories. The IPO price was Rs 70